SHANGHAI, China, July 15 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (OTC Bulletin Board: CHBT) ("China-Biotics," "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced the appointment of American Stock Transfer & Trust Company ("AST") as its new transfer agent and registrar, effective August 15, 2008. AST, headquartered in New York, New York, replaces the Company's former transfer agent and registrar, American Registrar & Transfer Company.
Consistently ranked #1 in the prestigious Group Five survey, AST has pioneered a unique, customer-driven approach to the provision of comprehensive transfer agency services. Founded in 1971, AST has grown to be the largest independent stock transfer agent in the United States.
Stockholders seeking information regarding stock transfer, lost
certificates, and address changes may contact AST as follows:
For General Information
American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY
Stockholder Toll-Free line: 1-800-937-5449
World Wide: 1-718-921-8200
About China-Biotics, Inc.
Headquartered in Shanghai, China-Biotics, Inc. ("China-Biotics", "the Company") was founded in 1999 and is one of China's largest suppliers of probiotics. Probiotics are beneficial live bacteria used as dietary supplements and food additives to improve intestinal health and digestion. The Company's product portfolio contains live microbials made with proprietary technology. Currently, these products are sold over-the-counter under the "Shining" brand through large distributors to more than 1,000 pharmacies and 100 supermarkets in Shanghai, Jiangsu and Zhejiang. Shining is one of the most recognized brands in Shanghai. China-Biotics plans to expand its retail sales to other major cities in China and is launching 300 Shining brand logistic centers in these cities. The Company's flagship product, "Shining Essence", has been a profit driver since its launch in April 2001. There is a significant demand for probiotics for use in the bulk additive market, which is currently met by imports. China-Biotics is building a new plant which will increase its production capacity manifolds to capture this market. For more information, please visit http://www.chn-biotics.com .
Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995: Any statements set forth above that are not historical facts
are forward-looking statements that involve risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements. Such factors include, but are not limited to,
the Company's ability to market existing and new products, ability to
access capital for expansion, changes from anticipated levels of sales,
future national or regional economic and competitive conditions, changes in
relationships with customers, dependence on its flagship product profits
and other factors detailed from time to time in the Company's filings with
the United States Securities and Exchange Commission and other regulatory
authorities. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
For more information, please contact:
CCG Investor Relations
Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
|SOURCE China-Biotics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved